(S1 (S (S (NP (NP (NN IL-12) (NN inhibition)) (PP (IN of) (NP (NP (JJ endothelial) (NN cell) (NNS functions)) (CC and) (NP (NN angiogenesis))))) (VP (VBZ depends) (PP (IN on) (NP (JJ lymphocyte-endothelial) (NN cell) (NN cross-talk))))) (. .)))
(S1 (S (S (NP (ADJP (ADJP (FW In) (FW vivo)) (ADJP (JJ IL-12-dependent))) (NN tumor) (NN inhibition)) (VP (VBZ rests) (PP (IN on) (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (NN IL-12))) (S (VP (TO to) (VP (VP (VB activate) (NP (DT a) (JJ CD8-mediated) (NN cytotoxicity))) (, ,) (VP (VB inhibit) (NP (NN angiogenesis))) (, ,) (CC and) (VP (VB cause) (NP (JJ vascular) (NN injury)))))))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (ADJP (FW in) (FW vivo)) (NNS studies)) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (S (NP (JJ such) (NN inhibition)) (VP (VBZ stems) (PP (IN from) (NP (NP (NP (JJ complex) (NNS interactions)) (PP (IN of) (NP (JJ immune) (NNS cells)))) (CC and) (NP (NP (DT the) (NN production)) (PP (IN of) (NP (NP (NN IFN-gamma)) (CC and) (NP (JJ other) (JJ downstream) (JJ angiostatic) (NNS chemokines)))))))))))))) (, ,) (NP (NP (DT the) (NNS mechanisms)) (VP (VBN involved))) (VP (VBP are) (ADVP (RB still)) (VP (ADVP (RB poorly)) (VBN defined)))) (. .)))
(S1 (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP show) (SBAR (IN that) (S (NP (NN IL-12)) (VP (VBZ activates) (NP (NP (DT an) (JJ anti-angiogenic) (NN program)) (PP (IN in) (NP (NP (NP (NN Con) (JJ A-activated) (NN mouse) (NN spleen) (NNS cells)) (PRN (-LRB- -LRB-) (NP (JJ activated) (NN spc)) (-RRB- -RRB-))) (CC or) (NP (NP (JJ human) (NN PBMC)) (PRN (-LRB- -LRB-) (NP (VBN activated) (NN PBMC)) (-RRB- -RRB-)))))))))) (. .)))
(S1 (S (NP (NP (DT The) (JJ soluble) (NNS factors)) (NP (PRP they))) (VP (VP (VB release) (PP (IN in) (NP (NP (PRP$ its) (NN presence)) (VP (NN arrest) (NP (NP (DT the) (NN cycle)) (PP (IN of) (NP (NP (JJ endothelial) (NNS cells)) (PRN (-LRB- -LRB-) (NP (NN EC)) (-RRB- -RRB-))))))))) (, ,) (VP (VB inhibit) (NP (ADJP (FW in) (FW vitro)) (NN angiogenesis))) (, ,) (VP (ADVP (RB negatively)) (VB modulate) (NP (NP (DT the) (NN production)) (PP (IN of) (NP (NN matrix) (NN metalloproteinase-9))))) (, ,) (CC and) (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (NN EC))) (S (VP (TO to) (VP (VP (VB adhere) (PP (TO to) (NP (NN vitronectin)))) (CC and) (VP (VB up-regulate) (NP (NP (NP (NN ICAM-1)) (CC and) (NP (NN VCAM-1))) (NN expression)))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS effects)) (VP (VP (VBP do) (RB not) (VP (VB require) (NP (JJ direct) (JJ cell-cell) (NN contact)))) (, ,) (CC yet) (VP (VBP result) (PP (IN from) (NP (NP (JJ continuous) (NN interaction)) (PP (IN between) (NP (NP (VBN activated) (JJ lymphoid) (NNS cells)) (CC and) (NP (NNS EC))))))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBD used) (NP (NN neutralizing) (NNS Abs)) (S (VP (TO to) (VP (VB show) (SBAR (IN that) (S (NP (NP (DT the) (JJ IFN-inducible) (NN protein-10)) (CC and) (NP (ADJP (JJ monokine-induced) (PP (IN by) (NP (NN IFN-gamma)))) (NNS chemokines))) (VP (VBP are) (ADJP (JJ pivotal) (PP (IN in) (S (VP (VBG inducing) (NP (DT these) (NNS effects)))))))))))))) (. .)))
(S1 (S (NP (NP (NNS Experiments)) (PP (IN with) (NP (NP (NN nu/nu) (NNS mice)) (, ,) (NP (NN nonobese) (JJ diabetic-SCID) (NNS mice)) (, ,) (CC or) (NP (NP (VBN activated) (NN spc)) (VP (VBN enriched) (PP (IN in) (NP (JJ specific) (NN cell) (NNS subpopulations)))))))) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (NP (ADJP (JJ CD4-LRB-+-RRB-))) (, ,) (NP (ADJP (JJ CD8-LRB-+-RRB-))) (, ,) (CC and) (NP (NN NK) (NNS cells))) (VP (VBP are) (ADVP (RB all)) (VP (VBN needed) (S (VP (TO to) (VP (VB mediate) (NP (NP (DT the) (JJ full) (JJ anti-angiogenetic) (NN effect)) (PP (IN of) (NP (NN IL-12)))))))))))) (. .)))
